Stifel initiated coverage of BillionToOne (BLLN) with a Buy rating and $145 price target The firm says the company “has made a strong foray” into established portions of the olecular diagnostics market. BillionToOne is taking share in a way that is driving growth well beyond peers given its “meaningful performance and workflow advantages,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- BillionToOne initiated with an Overweight at JPMorgan
- BillionToOne initiated with an Overweight at Piper Sandler
- BillionToOne initiated with a Hold at Jefferies
- BillionToOne, Inc.: Strong Market Position and Profitability Justify Buy Rating
- BillionToOne’s Innovative Platform Poised for Growth in Reproductive Health and Oncology Markets